Clinical and Regulatory Development of Antibiofilm Drugs: The Need, the Potential, and the Challenges - Antibiofilm Agents: From Diagnosis to Treatment and Prevention - page 470

Table 1 (continued)
Company Antibiofilm evidence a Drug Type of molecule Clinical stage Therapeutic indication

MerLion Pharmaceu-
ticals (partner
with Alcon for
ear infections)
http://www.
merlionpharma.
com

Finfloxacin Fluoroquinolone anti-

biotic, novel low pH
activated form

Phase 3 for acute otitis
media initiated 4/2012

Company website, press
releases

Complicated UTI and
pyelonephritis

Phase 2 for UTI initiated
12/2012
QIDP and Fast Track
Status granted by
FDA for oral and IV
use for complicated
urinary tract infec-
tions (UTIs)

H. pylori infections
Topical formulation for
acute otitis externa and
otitis media being
developed with Alcon

Microbion Corp.
http://www.
microbioncorp.
com

BisEDT Bismuth-thiol Phase 1 completed in the

UK

Company website, press
releases, multiple
peer-reviewed
publications

Gel formulation for local
administration for
postsurgical orthope-
dic infections

Bismuth-1,2-
ethanedithiol Phase 2 ready for ortho-

pedic infections in the
USA Topical gel for chronic

wound infections;
skin, burn, and surgi-
cal site infections

QIDP Designation
awarded by FDA for
postsurgical orthope-
dic infections

Nova Bay Pharma-
ceuticals
(partnered with
Galderma for
dermatology)
http://www.novabay.
com

NVC-422 Aganocide Currently enrolling Phase

2 for urology, Phase 2b
for ophthalmology,
and Phase 2b with
Galderma for skin
infections

Early website, publica-
tions, press releases
but no mention in
more recent publicity

Impetigo

Auriclosene: N , N -
dichloro-2,2-
dimethyltaurine

Urological infections,
viral conjunctivitis
(eye)

2011 and 2012 peer-
reviewed publications
show efficacy in sheep
biofilm infection